In-vivo PET studies also revealed reduced binding to the benzodiazepine binding site of the GABAA receptor in patients affected by fragile X syndrome in one portion of the PFC (98), exactly as observed in the Fmr1 KO mice at 12 weeks (Figure 3F). The gene discussed is FMR1; the disease is fragile X syndrome.